回到家总会感觉好些，有时人在医院里，小病也会觉得很严重，环境使然。

愿老人家一切都好起来。

又几天过去了。点滴打完了吗？

愿一切保重！

我们爱的人，爱我们的人：

一切保重！

引用

下面是引用Ar-Ping于2005-06-06 21:50发表的:


血管不行了? 情形怎么样?
我爸爸那时候, 血管渗透, 啥针扎进去都会漏, 因为血管都硬化了.

.......

开始有些这样的症状，不过，后来我们网上看到，可能是对一种常规治疗
药物反应过大。昨天的点滴好些了。谢谢！

不知道前面还会有什么，不过，我们会面对;)

引用

下面是引用多余于2005-06-06 21:33发表的:
我才看到这篇你的记录. 真是太难为你了，在这期间还不忘安慰我.  

不知道该说什么好, 祈求你和妈妈都平安,顺利.

面对这些,除了坚强,乐观, 还是坚强,乐观 ,再坚强,乐观!
.......

。。。。。不知道跟你说什么，有友如你，我也很知足了。
不论生活里面碰到什么事情，自己还是自己。
妈妈虽然生病了，可是我恰好在国内可以陪着她，我也很知足。。。
从这件事情上我也感受到了更多，对自己，对家人，对朋友，对生命。。。。

虽然那天我说，很多人都是以为别人活着作为自己的生存动力，其实
我觉得只有真正意义上自我独立，为了自己确定的追求活着，这样
才会不以物喜，不以己悲。

引用

下面是引用chat于2005-06-04 05:19发表的:
妈妈说，我真的帕点滴了，血管不行了。

.......

血管不行了? 情形怎么样?
我爸爸那时候, 血管渗透, 啥针扎进去都会漏, 因为血管都硬化了.

千言万语, 保重. 坚强.

我才看到这篇你的记录. 真是太难为你了，在这期间还不忘安慰我.  

不知道该说什么好, 祈求你和妈妈都平安,顺利.

面对这些,除了坚强,乐观, 还是坚强,乐观 ,再坚强,乐观!

我哭了.....................

.............................................

.............................................

Gene Mutation Predicts Outcome For Lung Cancer Patients
Patients with the earliest form of the most common type of lung cancer are more than twice as likely to die of the disease within four years if they have a mutation in a well known cancer-causing gene, scientists have found. The study in the July 2 issue of the Journal of the National Cancer Institute also shows that lung cancer patients who both smoke and consume alcohol frequently are more likely to have the mutation.
A team led by surgeon Steven A. Ahrendt, M.D., of the James P. Wilmot Cancer Center at the University of Rochester analyzed tumors from 188 patients with non-small-cell lung cancer. The team found that the status of the p53 gene plays a pivotal role in distinguishing which patients are most likely to survive four years or more. The discovery comes at a time when complex molecular markers are beginning to play a role along with more traditional features such as the extent of cancer in a patient's body in determining the treatments that cancer patients receive.
"We need to confirm these results through a larger study, but this difference is large enough to be clinically meaningful," says Ahrendt, associate professor of surgery, oncology, and pathology.
The ability to predict which patients are more likely to live or die could cause doctors to re-think how they treat certain lung cancer patients Ahrendt says. Currently, patients with early-stage lung cancer commonly receive surgery but not chemotherapy or radiation unless the cancer recurs. If scientists know that certain patients – for instance, those with a p53 mutation – are much more likely to die of the disease, preventive chemotherapy might be considered earlier in treatment.
The study creates a bright spot for a disease where the overall survival rate is dismal. Lung cancer is the leading cause of death by cancer in both men and women, and overall, fewer than one in five patients live five years after diagnosis. For people whose lung cancer is caught in the earliest stage, the news is somewhat better: Generally about 40 to 60 percent of such patients live five years. Ahrendt's study identifies a sub-group of patients – those whose cancer is caught early, who don't have a p53 mutation – in which 78 percent of patients, nearly four in five, lived four years or more, a survival rate four times higher than for lung cancer patients overall.
Ahrendt and colleagues base the findings on an extensive study of tumor samples from 188 patients with non-small-cell lung cancer, which make up 80 percent of lung cancers. The team found mutations of the p53 gene – a gene whose normal function is to produce a protein that helps repair or destroy damaged cells before they can become troublesome – in 55 percent of the tumors. In the study, 48 percent of early-stage lung cancer patients with a p53 mutation died within four years, compared to 22 percent of patients without the mutation.
The team found that the type of p53 mutation matters as well. Patients with mutations that simply substituted one chemical base for another fared better than patients with more complicated mutations that completely knocked out the function of the tumor-suppressing protein made by p53.
The finding pertains only to those patients with very early lung cancer, which has not spread to lymph nodes or any other organs. The status of the p53 gene does not appear as crucial for later-stage cancers, probably because mutations in the p53 gene are overshadowed by the larger number of genetic abnormalities in these tumors.
The scientists also found that people who smoked and consumed alcohol frequently were 50 percent more likely to carry the mutation than smokers who did not regularly drink alcohol. While it's widely known that most people who get lung cancer are smokers, the evidence points out that once they get lung cancer, smokers who drink alcohol are more prone to have p53 mutations that make it more likely that they will die from the disease.
Ahrendt says the results of several dozen other studies that have looked at the relationship between p53 and lung cancer have varied widely, with some suggesting a link between p53 and survival, and others finding no such link. Some of the factors that set apart the current study, Ahrendt says, are its large size and its design as a "prospective" study in which scientists did not know the patient outcomes when the study began.
Most important, he says, the team used two very different techniques to check p53. In addition to conventional sequencing technology to check whether p53 had mutated, the team also used gene-chip technology to analyze the gene's genetic sequence. Together the techniques picked up more p53 mutations than previous studies.
Currently there is no easy, inexpensive blood test to check one's p53 status, Ahrendt says. The molecule is a popular pharmaceutical target for drugs in development because it's involved in many types of cancerous tumors, including breast, ovarian, bladder, brain and prostate cancers.
Other authors on the paper include researcher Yingchuan Hu and statistician Michael McDermott of the University of Rochester, and David Sidransky, Martin Buta, Nicole Benoit, Stephen C. Yang, and Li Wu of Johns Hopkins. With funding from the National Cancer Institute, the team analyzed tumors from patients where Ahrendt previously worked, at Johns Hopkins in Baltimore and at the Medical College of Wisconsin in Milwaukee.

This story has been adapted from a news release issued by University Of Rochester Medical Center.

test

Source: Washington University School Of Medicine
Date: 2004-04-19
URL: http://www.sciencedaily.com/releases/2004/04/040415010103.htm

--------------------------------------------------------------------------------

Lung Tumor Therapies Improved By Combining CT And PET Scans
St. Louis, April 14, 2004 -- Physicians targeting lung tumors for radiation therapy can substantially improve their aim by combining data from two scanning techniques, according to Washington University researchers at Siteman Cancer Center and Barnes-Jewish Hospital in St. Louis.

The current standard practice is to devise radiation therapy targets based solely on computerized tomography (CT) scans, which produce detailed pictures of the size and shape of cancerous growths.

In a study in the April 15 issue of the International Journal of Radiation, Oncology, Biology, Physics, researchers show that adding data from positron emission tomography (PET) scans to structural CT data significantly enhances radiologists' abilities to precisely define the locations of tumors for radiation treatments. Radiologists use PET to get detailed information on tissue function and activity, enabling them to highlight such differences as the increased metabolic activity of a tumor.

For the study, researchers compared therapy plans designed by different physicians for 26 lung cancer patients. Two therapy plans were devised for each patient: A physician with access only to CT scanning results created one of the plans, while another physician independently created a second therapy plan based on combined data from CT and PET scans. Patients had non-small-cell lung cancer, the most common type of lung tumor.

"Adding the PET data to the analysis changed and improved the treatment plans 58 percent of the time," says lead investigator Jeffrey D. Bradley, M.D., assistant professor of radiation oncology. "PET-CT helped physicians more accurately identify where tumors were in patients, and that's very important to efficacy of treatment and to limiting side effects."

As an example of improved effectiveness, Bradley cited a patient whose tumor had caused a lung to collapse. With a CT scan only, physicians had identified a significant portion of the collapsed lung as tumor. However, with a combined PET-CT image, they were able to show that the tumor was much smaller.

Combined PET-CT scanning units, first devised approximately two years ago, are now available at hundreds of hospitals nationwide, according to Bradley.

"Papers like this are intended both to help change the community standard for how radiation treatment protocols are designed and to change insurers' willingness to pay for this new approach," Bradley says. "This is the next advance in radiology, and it could be very helpful to our patients."

Bradley is designing a multi-institutional follow-up study for the Radiation Therapy Oncology Group, a cooperative group funded by the National Cancer Institute.

###


Bradley J, Thorstad WL, Mutic S, Miller TR, Dehdashti F, Siegel BA, Bosch W, Bertrand RJ. Impact of FDG-PET on Radiation Therapy Volume Delineation in Non-Small-Cell Lung Cancer. International Journal of Radiation Oncology, Biology, Physics, April 15, 2004.

Funding from the Siteman Cancer Center supported this research.

The full-time and volunteer faculty of Washington University School of Medicine are the physicians and surgeons of Barnes-Jewish and St. Louis Children's hospitals. The School of Medicine is one of the leading medical research, teaching and patient care institutions in the nation, currently ranked second in the nation by U.S. News & World Report. Through its affiliations with Barnes-Jewish and St. Louis Children's hospitals, the School of Medicine is linked to BJC HealthCare.

Source: University Of Pennsylvania Medical Center
Date: 2004-08-05
URL: http://www.sciencedaily.com/releases/2004/08/040805091402.htm

--------------------------------------------------------------------------------

Penn Researchers Offer New Hope To Advanced Stage Lung Cancer Patients
Philadelphia, PA -- A new study that appears in the June 2004 issue of the Journal of Clinical Oncology shows that the life-expectancy of patients with advanced stage lung cancer can be extended with the use of photodynamic therapy, or PDT, in addition to surgical intervention. Typically, advanced stage non-small cell lung cancer patients have a median survival of 6-9 months when treated with the current standard of care, chemotherapy alone. However, this same set of patients demonstrated a median survival of more than 22 months when chemotherapy was combined with surgery and intraoperative PDT, a new laser-based cancer treatment. Joseph S. Friedberg, MD, Chief of Thoracic Surgery at Presbyterian-University of Pennsylvania Medical Center, Stephen Hahn, MD, Clinical Associate Professor of Radiation Therapy and James P. Stevenson, MD, Assistant Professor of Medicine are the co-investigators in this trial at the University of Pennsylvania Medical Center.

“We consider these results preliminary but extremely encouraging. We expected PDT to make a difference in the rate of local recurrence and it has,” says Dr. Friedberg, “However, we did not anticipate the dramatic increase in survival that we have observed. In addition to the local control, there must be some sort of systemic immune response that is contributing to the enhanced survival we are observing in these patients with a very advanced form of the disease. We are exploring this phenomenon at a number of levels and feel we may have stumbled upon the makings of a new immunologic approach to treating patients with all stages of lung cancer. It is an area of research about which we are very excited and actively pursuing.”

In PDT, a nontoxic photosensitizing agent, Photofrin, is injected into the blood stream and concentrates in cancer cells, allowing the cancer to become very sensitive to light. Using a laser to shine light on these cells results in a very effective mechanism for killing cancer cells. The damage occurs only where the light is shined, limiting the harm to healthy tissue. PDT has rarely been used in this way, combining it with other treatment modalities, although it has been used by clinicians for treating small, easily visualized tumors in the windpipe and esophagus. Patients eligible for the treatment are those whose cancer has spread within the chest cavity.

In the study, each patient is treated with chemotherapy until the cancer stops responding, the normal course for this disease and the limitation of chemotherapy alone. After it is confirmed that the cancer has not spread beyond the chest cavity, the patient then receives Photofrin 24 hours prior to surgery. During surgery, the cancer is removed, which may involve excising all or part of the affected lung. Then, surgeons shine a laser into the chest cavity, giving the appropriate dose of light in an effort to kill any remaining microscopic tumor cells that remain after surgery.

It is known that surgery, without PDT, will almost certainly be accompanied by a high rate of local recurrence, likely a result of the invisible remaining disease being targeted with PDT. The treatment has proven very safe, largely as a function of using a specially designed computer system to measure and monitor the amount of laser light delivered at the time of treatment.

Editor's Note: The original news release can be found here.

写好，　忘了发了。

拉出去，　暴打一顿！



看样子老伍很知道我的情况地说。。。

以下是你的职务职称问题的批示：

交董事会研究决议！

我是看了这里的短信啊。有别人的，可是没有troublemaker的。。

引用

下面是引用chat于2005-03-21 03:50发表的:
troublemaker
没有收到你的短信啊。

呵呵，茶包说的短信不在你的手机里，当然也不在移动电话里，而是在论坛里给你的短信，在页面右上角 控制面板 · · 短消息 · 查看新贴，这个短消息用于本论坛朋友只间传递一些私人的信息，只有收件人可以看到(相当于一个小信箱吧！)。

茶包已经在短信中告诉了你她的email地址，请你跟她联系(不是说只有收件人可以看到吗？我怎么就知道了呢？)。

咦？我这么热心论坛建设，怎么着也该享受一个副科级待遇吧？是该跟老大反应一下我的职称职务问题了。呵呵。。。

troublemaker
没有收到你的短信啊。

谢ＣＨＡＴ！

请看短信！

还有，原来我妈妈试过用天麻和瘦肉煮了吃。有些缓解。

神经性头痛很难受的，我小时候看着妈妈怎么过来的。trouble，你能够这么照顾一家人，一定很不容易。你也一定保持一个好心情啊！不要太操心，操劳了。

嗯。妈妈治病大概10年以前，现在那个神婆是否还给普通人看病，或者是否还在我都不知道了。我可以帮你问一下他们单位的人，可以给我留个邮件么？那个单位是军方高级技术单位,不便公开。